At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02137 BRII-B
Not Yet Opened 06-18 16:08:07
1.030
+0.050
+5.10%
High1.040
Low0.950
Vol899.00K
Open0.980
D1 Closing0.980
Amplitude9.18%
Mkt Cap743.66M
Tradable Cap743.66M
Total Shares722.00M
T/O884.28K
T/O Rate0.12%
Tradable Shares722.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%
Brii Biosciences Ltd is a biotechnology company primarily engaged in the development of therapies for infectious diseases and central nervous system diseases. The Company's main products include BRII-179, a candidate drug for hepatitis B virus (HBV) immunotherapy, Tobevibart, an investigational neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg), as well as soralimixin (BRII-693), a synthetic lipopeptide for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacterial infections. The Company primarily operates its businesses in the domestic market.